AU2012214396B2 — Methods for treating pulmonary hypertension
Assigned to Chiesi Farmaceutici SpA · Expires 2017-04-27 · 9y expired
What this patent protects
The present invention relates to methods for treating or preventing pulmonary hypertension, reducing mortality in a subject experiencing pulmonary hypertension, or inhibiting ADP-mediated vasoconstriction of pulmonary arteries in a subject, comprising administering to the subject…
USPTO Abstract
The present invention relates to methods for treating or preventing pulmonary hypertension, reducing mortality in a subject experiencing pulmonary hypertension, or inhibiting ADP-mediated vasoconstriction of pulmonary arteries in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a reversible P2Yi2 receptor antagonist. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments.
Drugs covered by this patent
- Kengreal (CANGRELOR) · Chiesi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.